Physician profile
Robert M Cannon
NPI 1215373139
$1,972.70
in general payments reported to CMS, 2019-2025
28 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $243 · 2021: $291 · 2022: $275 · 2023: $133 · 2024: $245 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.91 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Astrazeneca Pharmaceuticals LP | $378.01 | 2020-2025 | Breztri, Farxiga |
| Amgen INC. | $145.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $118.23 | 2019-2022 | |
| Astellas Pharma US INC | $111.05 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $88.16 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $83.57 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.61 | 2019-2025 | |
| Lilly USA, LLC | $66.62 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $66.04 | 2019-2025 | |
| Abbvie INC. | $43.23 | 2023-2025 | Vraylar |
| Stryker Corporation | $42.27 | 2025 | Clottriever Bold Catheter |
| Lundbeck LLC | $40.27 | 2024 | Vyepti |
| Genentech USA, INC. | $39.02 | 2019 | |
| Arbor Pharmaceuticals, INC. | $32.35 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.17 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.86 | 2020-2022 | |
| Inspire Medical Systems, INC. | $22.56 | 2025 | Inspire |
| Mylan Specialty L.P. | $22.41 | 2024 | Yupelri |
| Eisai INC. | $22.19 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.73 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $15.86 | 2020 | |
| Allergan, INC. | $15.48 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.87 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.61 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $14.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.30 | 2022 | |
| Boston Scientific Corporation | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.